Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777960 | 0.92 | PDE5A (0.58) | PDE5A | |
| SCHEMBL6777036 | 0.90 | PDE5A (0.62) | PDE5APDE6C | |
| SCHEMBL6631130 | 0.87 | PDE5A (0.75) | PDE5APDE6C | |
| SCHEMBL6776186 | 0.87 | PDE5A (0.66) | PDE5APDE6C | |
| SCHEMBL6775811 | 0.86 | PDE5A (0.64) | PDE5APDE6C | |
| SCHEMBL6776801 | 0.85 | PDE5A (0.79) | PDE5APDE6C | |
| SCHEMBL3580414 | 0.82 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6773144 | 0.81 | PDE5A (0.59) | PDE5APDE6C | |
| SCHEMBL6776663 | 0.81 | PDE5A (0.62) | PDE5APDE6C | |
| SCHEMBL6776248 | 0.79 | PDE5A (0.56) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794387-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (CGMP PDE5) INHIBITORS; 2-(5-ACETYL-2-BUTOXY-3-PYRIDINYL)-7-ETHYL-5-METHYLIMIDAZO(5,1 -F)(1,2,4)TRIAZIN-4(3H)-ONE FOR EXAMPLE | PFIZER INC. | 2004-09-21 | — | — | US | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1380293-A1 | BONE METABOLISM IMPROVING AGENTS | The Nisshin OilliO, Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20020177599-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177599-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.